Long-term efficacy and safety of anlotinib in advanced sarcomas.

• DOI: 10.1200/jco.2022.40.16_suppl.e23564
• Publication Date: 2022-06-06T17:43:51Z
• Authors: Weitao Yao; Xinhui Du; Jiaqiang Wang; Peng Zhang; Xiaohui Niu; Xin Wang
• Keywords: Synovial Sarcoma; Undifferentiated Pleomorphic Sarcoma; Clear-cell sarcoma

e23564 Background: Treatment of sarcomas has advanced in recent years partly because the application multitarget tyrosine kinase inhibitor (TKI) drugs. Anlotinib is an oral TKI with dual effects antiproliferation and antiangiogenesis, it a therapeutic effect good tolerance low side effects. In theory, physicians can gain long-term tumor control anlotinib certain sarcomas. Methods: We conducted retrospective analysis patients measurable target lesions who had been treated our ward since 2018. There were 22 taken regularly for more than 12 months. Their general information, clinical efficacy, toxicities statistically analyzed. used swimmer plot to observe efficacy duration drugs waterfall express best treatment effect. Results: 14 male 8 female patients, ranging age from 75 (44.77 on average) years. The primary ASPS five cases; synovial sarcoma (SS) four LMS three epithelioid (ES) UPS two cases each; clear cell sarcoma, RMS, angiosarcoma (AS), fibrosarcoma (FS), pleomorphic liposarcoma (LS), osteosarcoma (OS) one case each. sites metastasis lung 15 cases, lymph nodes 4 multiple 3 cases. Therapies as follows: first-line therapy (6 cases), second-line (9 third-line (5 (2 cases). current protocols nine alone, combination chemotherapy, immunotherapy (anti-PD1). this group was complete response (CR) (18.18%), partial (PR) (22.73%), stable disease 13 (59.09%), overall rate 40.91% longest lasting time 26, 16, 38 months different groups. mean progression-free survival (PFS) 23.32 main adverse included myelosuppression seven (31.82%), hypertension (13.64%), hand-foot syndrome weakness (9.10%). Severe hypothyroidism wound ulceration pneumothorax formation another case. Conclusions: monotherapy or be effective safe choice some longer maintenance acceptable Besides, combined anti-PD1 better specific diseases such ES. chemotherapy SS, LMS, FS, RMS. Clinical CR PR may prediction PFS